Malaysia Probiotic BCMC® Strains Help Manage NCDs Better

It was great news for Malaysia’s medical community yesterday when it was unveiled at Sunway Resort that a medical breakthrough research of probiotic BCMC® strains has been achieved by one of Malaysia’s leading pharmaceutical players – B-Crobes Laboratory Sdn. Bhd. (B-Crobes). B-Crobes and Gut Research Group, Faculty of Medicine, Universiti Kebangsaan Malaysia (UKM) found studies that show the probiotic BCMC® strains could work as a complementary therapy for Non-Communicable Diseases (NCDs).

B-Crobes and Gut Research Group, UKM members

What are the Probiotic BCMC® Strains?

The probiotic BCMC® strains that B-Crobes has researched, developed, and manufactured consist of Lactobacillus acidophilus BCMC® 12130, Lactobacillus casei subsp. BCMC® 12313, Lactobacillus lactis BCMC® 12451, Bifidobacterium longum BCMC® 02120, Bifidobacterium bifidum BCMC® 02290, and Bifidobacterium infantis BCMC® 02129.

These BCMC® strains had been tested and undergone over 20 clinical studies to prove that the probiotic BCMC® strains can help improve and manage NCDs, specifically in Colorectal Cancer, Post-Gestational Diabetes (pregnant women with diabetes), Parkinson’s disease, and Non-Alcoholic Fatty Liver Disease (NAFLD). Throughout clinical studies, B-Crobes have found the safety and efficacy of the product.

Hence, the name HEXBIO was born.

HEXBIO has been used in intensive care units (ICU) in government hospitals and clinics across Malaysia. This product is also sold at pharmaceutical stores internationally including the UAE, Bahrain, China, Oman, Singapore, Philippines, and more.

What studies done on the Probiotic BCMC® strains?

The first study was done on post-surgical colorectal cancer patients. Two groups were formed. The first group was given placebos and the second group was given the probiotic BCMC® strains, during the 6 months recovery period. It is found that patients taking the probiotic BCMC® strains have a significant reduction in the level of specific pro-inflammatory cytokines (also known as harmful substances). These inflammatory cytokines could cause poor outcomes for the patients and contribute to further development and recurrence of colorectal cancer.

Another study was done on post-gestational diabetes women. The tests are done on postpartum women with a history of gestational diabetes mellitus (GDM) – which meant, these women had diabetes due to their pregnancy and diabetes did not reduce even after delivery. For a total of 3 months, postpartum women with a history of GDM were divided into two groups. One group was given placebos and the other group was given probiotic BCMC® strains. It is found that women taking the probiotic BCMC® strains had significant improvements in their insulin resistance, which is an important factor in managing post-gestational diabetes, thus decreasing the risk of developing diabetes mellitus Type 2.

Studies of the effect of probiotic BCMC® strains were also done on NAFLD (Non-alcoholic Fatty Liver Disease) patients. Two studies were done which is to see the effect of probiotics BCMC® on:

  • Hepatic Steatosis, Small Intestinal Mucosal Immune Function, and the Intestinal Barrier
  • Small Intestinal Microbiota Composition, Inflammatory Cytokines, and Intestinal Permeability

Similar to the other studies, NAFLD patients were divided into two groups where one group was given placebos and the other group was given the probiotic BCMC® strains for a period of 6 months. Through this study, it was found that the BCMC® strains managed to stabilize the mucosal immune function that protects NAFLD patients against intestinal permeability (prevents toxins from entering the intestines). It was also found that NAFLD patients that had taken the probiotic BCMC® strains have a well-balanced microbiota composition, giving them a healthy gut, and helping NAFLD patients maintain overall better health.

Further Research and Development on Probiotic-related Research

Mr Dean Lee, Executive Director of B-Crobes announced that B-Crobes would be collaborating with Universiti Kebangsaan Malaysia (UKM) and Sunway University to take the clinical application of probiotics and gut microbiomes to greater heights, especially for the medical community.

In doing so, B-Crobes have provided an RM50,000 educational research grant to both Faculty of Medicine, UKM, and the School of Medical and Life Sciences, Sunway University. B-Crobes is also giving scholarships to two full-time Ph.D. students from both universities to conduct probiotic-related research in Malaysia.

Mr Dean Lee, Executive Director B-Crobes Group of Companies
RM50,000 grant allocation to Sunway University
RM50,000 grant allocation to UKM

Who can consume HEXBIO?

The Probiotic BCMC® strain named HEXBIO is not only available for those with NCDs, but it is also safe to be consumed by healthy individuals, adults, and children alike, in order to prevent any gut-related diseases that can further evolve into NCDs. Children as young as 1-year-old can also consume the probiotic safely. Children who are picky eaters oftentimes would experience constipation – the same as elderlies with multiple chronic co-morbidities – and a healthy gut with well-balanced and good probiotics could further such issues from prolonging.

HEXBIO starts from as low as RM47 (travel/starter pack). Get yours today directly from the B-Crobes website or pharmacies near you.

Leave a Reply

Your email address will not be published. Required fields are marked *